• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.

作者信息

Hwang Michael, Seiwert Tanguy Y

机构信息

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA; The Bloomberg Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.

出版信息

Lancet Oncol. 2021 Apr;22(4):413-415. doi: 10.1016/S1470-2045(21)00121-2. Epub 2021 Mar 5.

DOI:10.1016/S1470-2045(21)00121-2
PMID:33684371
Abstract
摘要

相似文献

1
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.紫杉烷类药物会是头颈癌治疗的未来吗？免疫治疗时代的务实态度。
Lancet Oncol. 2021 Apr;22(4):413-415. doi: 10.1016/S1470-2045(21)00121-2. Epub 2021 Mar 5.
2
Two cases of combination therapy with cetuximab, paclitaxel, and cisplatin for advanced head and neck cancer.两例西妥昔单抗、紫杉醇和顺铂联合治疗晚期头颈癌的病例
J Oncol Pharm Pract. 2018 Oct;24(7):553-554. doi: 10.1177/1078155217722406. Epub 2017 Aug 1.
3
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.多西他赛、顺铂和 5-氟尿嘧啶诱导化疗联合西妥昔单抗放疗治疗局部晚期头颈部鳞状细胞癌。
Eur J Cancer. 2013 Jan;49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14.
4
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.多西他赛联合西妥昔单抗化疗后局部复发口咽癌的长期缓解
Eur Arch Otorhinolaryngol. 2016 Jun;273(6):1629-36. doi: 10.1007/s00405-015-3673-y. Epub 2015 Jun 5.
5
Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled?紫杉烷类药物纳入头颈部鳞状细胞癌一线化疗：承诺是否兑现？
Curr Opin Oncol. 2000 May;12(3):221-8. doi: 10.1097/00001622-200005000-00007.
6
Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?多西他赛联合顺铂加氟尿嘧啶与卡铂加氟尿嘧啶-西妥昔单抗用于既往未接受新辅助或辅助化疗的复发或转移性头颈部鳞状细胞癌患者一线治疗，哪种方案为标准方案？
J Cancer Res Ther. 2017 Jul-Sep;13(3):510-513. doi: 10.4103/0973-1482.161933.
7
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.TPF诱导化疗联合顺铂和西妥昔单抗同步放疗用于不可切除的头颈部鳞状细胞癌
Head Neck. 2014 Nov;36(11):1555-61. doi: 10.1002/hed.23506. Epub 2013 Dec 18.
8
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.多西他赛、顺铂和卡培他滨诱导化疗，随后联合西妥昔单抗和放疗治疗局部晚期不可手术的头颈部鳞状细胞癌患者：一项 I-II 期研究。
Oncology. 2013;84(4):251-4. doi: 10.1159/000347232. Epub 2013 Feb 20.
9
Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.头颈部鳞状细胞癌（SCCHN）中全身用药的毒性；免疫治疗时代的新视角。
Crit Rev Oncol Hematol. 2017 Jul;115:50-58. doi: 10.1016/j.critrevonc.2017.04.011. Epub 2017 Apr 27.
10
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.多西他赛、顺铂和氟尿嘧啶用于不可切除的复发性或转移性头颈部鳞状细胞癌患者。
Auris Nasus Larynx. 2015 Oct;42(5):396-400. doi: 10.1016/j.anl.2015.02.009. Epub 2015 Feb 23.

引用本文的文献

1
Suppressing Anaphase-Promoting Complex/Cyclosome-Cell Division Cycle 20 Activity to Enhance the Effectiveness of Anti-Cancer Drugs That Induce Multipolar Mitotic Spindles.抑制后期促进复合物/周期蛋白依赖性激酶 20 活性以增强诱导多极有丝分裂纺锤体的抗癌药物的疗效。
Int J Mol Sci. 2024 Jun 7;25(12):6329. doi: 10.3390/ijms25126329.
2
Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics.免疫疗法：口腔癌治疗的第四个领域。
Indian J Otolaryngol Head Neck Surg. 2024 Jun;76(3):2257-2272. doi: 10.1007/s12070-024-04565-3. Epub 2024 Mar 10.
3
Noninvasive radiomic analysis of enhanced CT predicts CTLA4 expression and prognosis in head and neck squamous cell carcinoma.
基于增强 CT 的无创放射组学分析预测头颈部鳞状细胞癌中 CTLA4 的表达和预后。
Sci Rep. 2023 Oct 5;13(1):16782. doi: 10.1038/s41598-023-43582-0.
4
Circadian rhythm-related genes index: A predictor for HNSCC prognosis, immunotherapy efficacy, and chemosensitivity.昼夜节律相关基因指数：预测头颈部鳞状细胞癌的预后、免疫治疗疗效和化疗敏感性的指标。
Front Immunol. 2023 Mar 10;14:1091218. doi: 10.3389/fimmu.2023.1091218. eCollection 2023.
5
cGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel.微管靶向药物紫杉醇依赖 cGAS 诱导的促炎和免疫稳态作用。
Front Immunol. 2023 Mar 7;14:1127623. doi: 10.3389/fimmu.2023.1127623. eCollection 2023.
6
Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌的现有及新兴分子疗法
Cancers (Basel). 2021 Oct 30;13(21):5471. doi: 10.3390/cancers13215471.